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1. Introduction 
Melanoma is the most malignant cutaneous tumor. The incidence of melanoma accounts 
for the sixth place among malignant diseases, 5% of malignancies among men and 4% of  
malignancies among women; it stands for 1.4% of deaths caused by malignant disease 
(Fisher et al., 2008). The incidence of malignant melanoma has constantly been increasing 
and it has reached 3% per year in the last several years. At the beginning of the 20th 
century, the population risk for malignant melanoma was in the ratio 1:500 but today 1:73 
of women and 1:49 of men are at risk (Fisher et al., 2008).   It is anticipated that there will 
be 68,130 newly diagnose cases of melanoma and approximately 8,700 deaths from the 
disease in the USA (Jamal et al., 2010). Among the population aged between 20 to 39 years 
malignant melanoma is on the second place by incidence. Although the disease is more 
frequent among men, its incidence during the reproductive period is higher among 
women.  In Great Britain, the third of all diagnosed melanomas arise before 50 years of 
age and about 30% to 35% develop during the reproductive period of women (Anonymus, 
2003; Cancer Research UK 2006). The actual incidence of melanoma during pregnancy is 
unknown. Smith and Randall (Smith RS & Randall, 1969) gave the first reports based on 
the source documents of a small non-reference Plattsburg Air Force Base Hospital, New 
York. The incidence of melanoma was 2.8 per 1000 deliveries but studies that are more 
recent showed that it is between 2.8 and 5 per 100,000 of pregnancies; the registry of 
German Dermatological Society shows that 1% of female patients affected with melanoma 
is pregnant (Dillman et al., 1996; Garbe, 1993). A group of Swedish authors analyzed the 
period from 1973 to 1984 and reported that melanoma is the most common cancer 
appearing in pregnancy and accounts for 24.5% of cancer cases in pregnant women 
(Matthiasen & Berg, 1989). From 1958 to 1999, 19,337 women with melanoma were 
included in the most extensive epidemiology study based on Swedish and regional 
registries; 0.9% of malignant melanomas were diagnosed during the pregnancy. Of all 
included patients, 5,533 of women were in reproductive age and 185 (3.3%) of them were 
diagnosed with melanoma during the pregnancy (Lens et al., 2004.). The prognostic 
features for melanoma depend on the stage it has been diagnosed. Although the 5-year 
survival for stage IV melanoma is still less than 5%, overall mortality from melanoma has 
a decreasing tendency (Rigel et al., 1996). The effect of pregnancy to the course of 
melanoma has been a researching issue for years. The results of uncontrolled studies 
conducted from 1950 to 1980 show that pregnancy is an unfavorable prognostic factor in 
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patients’ survival (Pack & Scharnagel, 1951; Sutherland et al., 1983; Trapeznikov et al., 
1987 ), but the reports of recent controlled studies oppose this finding (Lens et al., 2004; 
Reintgen et al., 1985; McManamny  et al., 1989; Wong et al., 1989; Slingluff et al., 1990; 
MacKie et al., 1991). The most recent population studies demonstrate equal survival 
among women with the same melanoma stage regardless they are pregnant or not (Lens 
et al., 2004; O’Meara et al, 2005). Overall survival rate in both pregnant and nonpregnant 
patients was 82% (Lens et al., 2004).  
2. The influence of sex hormones on melanoma 
Sun exposure and excessive tanning are the main risk factors for melanoma developing 
(Katsambas et al., 1996; Lazovich et al., 2010). Because the appearance of malignant 
melanoma in reproductive period is more often in women than in men (Cancer research UK 
2006), the influence of sex hormones, exogenous hormones, and reproductive factors is a 
broadly investigated topic in the pathogenesis of melanoma ( Osterlind et al., 1988; Smith 
MA et al., 1998; Karagas et al., 2002; Pfahlberg et al., 1997; Durvasula et al., 2002; Elwood & 
Coldman, 1978).  
2.1 The influence of reproductive factors and exogenous hormones 
The length of exposure to female sex hormones has no influence on the risk of melanoma 
development. Osterlind et al. (Osterlind et al., 1988) included in their case-control study 280 
patients with melanoma and 536 patients in the control group. They showed that age of  
menarche, the length of reproductive period, the age of natural menopause appearance, the 
age of first pregnancy, the number of pregnancies, the number of live newborn infants, and 
the number of abortions has no influence on melanoma development. In addition, the 
results of the same study demonstrated that there is no correlation between melanoma 
appearance and the use of oral contraceptives, their type or time of usage. According to 
study metioned above, the use of hormone-replacement therapy does not increase the risk of 
melanoma development. Smith et al. (Smith MA et al., 1998) included in their study 308 
women with malignant melanoma and 233 patients in the control group. They investigated 
the influence of previous pregnancies, the age of the first pregnancy, the use of hormone-
replacement therapy, the use of oral contraceptives, and the age when first contraceptive 
was taken; they found that neither of these parameters had any influence on the increase of 
the risk of melanoma development. Menopause and body mass index did not have any 
specific effect to the risk of melanoma development but the incidence of melanoma was 
three times higher in obese postmenopausal women than in premenopausal women of 
average weight. This study also reported that multiple pregnancies could partly have 
protective influence on the development of melanoma. Two meta-analyses of case-control 
studies found no risk of melanoma development among women who used oral 
contraceptives. The age when first contraceptive was used, duration of contraceptive use, 
the length of the period from the first and the last use of contraceptives, and the type of 
contraceptives did not increase the risk of melanoma development (Karagas et al., 2002; 
Pfahlberg et al., 1997). The conclusion of Durvasula et al. (Durvasula et al., 2002) study is 
that there is no need to stop hormone-replacement therapy in patients treated of malignant 
melanoma because there is no evidence of the negative influence of this therapy to the 
patients’ survival. Although several studies demonstrated the protective effect of multiple 
pregnancies on melanoma development (Smith MA et al., 1998;  Karagas et al., 2006), the 
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results of the last case-control study conducted by Lea et al. (Lea, 2007) are opposite: women 
with multiple pregnancies are at higher risk for malignant melanoma.  
2.2 Estrogen receptors  
Estrogen effects are expressed by the activation of two estrogen receptors: ER┙ and ER┚. Up 
to the discovery of ER┚ in 1995, no immunohistochemical analysis pointed to the influence 
of ER in pathogenesis of malignant melanoma. Contrary to ER┙, which is predominant in 
breast tissue, ER┚ is characteristic for skin and other tissues that are not estrogen-
dependant, such as prostate, colon, and brain (de Giorgi et al., 2011). ER┚ distribution in 
skin depends on the sex and age of a person. Men have lower ER┚ level in skin than women 
in whom the level of this receptor decreases after menopause because of positive estrogen 
feedback loosing (Stevenson & Thornton, 2007).  Immunohistochemical and real-time 
polymerase chain reaction (PCR) analyses of ER┚ in the tissue of melanoma (de Giorgi et al., 
2009; Schmidt et al., 2006) showed that expression of ER┚ is reversely proportional to 
Breslow thickness, which is a significant prognostic factor for survival from melanoma 
(Rigel et al., 1996). De Giorgi et al. found lower ER┚ concentration in thicker and more 
invasive melanomas and concluded that ER┚ had an antiproliferative effect; hence their 
explanation for the failure of tamoxifen in the treatment of malignant melanoma (Lens et al., 
2003). The authors believe that tamoxifen inhibits ER┙ and ER┚ nonselectively and in this 
way, although it inhibits ER┙ proliferative effect, it inhibits antiproliferative effect of ER┚ 
(de Giorgi et al., 2011). The influence of estrogen receptors in melanoma pathogenesis is still 
to be cleared up in future.  
2.3 The impact of pregnancy 
The impact of pregnancies and other reproductive and hormonal factors on melanoma 
development has been described in previous chapters. Melanomas are relatively often 
diagnosed during pregnancies; it has led to the speculation that certain hormone effects and 
immunosuppression in pregnancy may induce malignant transformation (Sadoff et al., 1973; 
Cochran et al., 1982). However, none of the studies showed that the risk for melanoma 
occurring is higher during pregnancy. Perhaps, diagnosis of melanoma is more frequent 
because patients visits the physicians more regular. According to the Connecticut Tumor 
Registry, the percent of melanoma that are diagnosed among pregnant women equals the 
one among the general female population (Houghton et al.,1981). In addition, the percent of 
melanoma arisen by the transformation of existing nevus is from 62% to 68% in pregnant 
women (Houghton et al.,1981; Colboum et al., 1989), which is similar to 65% found among 
general female population (George  et al., 1960; Friedman et al., 1985).  
3. Diagnosis 
Diagnosis of melanoma in pregnancy does not differ from the diagnosis in other population 
and it comprises clinical examination, tumor excision or biopsy, and pathological 
examination. The classic ABCD system for melanoma detection was developed in 1985 by 
the American Cancer Society and it is the basis of clinical examination (Friedman et al., 
1985). ABCD is a simple method for early detection of malignant melanoma and its 
differentiation from benign nevi and other skin changes. The mnemonic ABCD is formed 
from the initial letters of the words Asymmetry, Border irregularity, Color variety, and 
Diameter greater than 6 mm (Figure 1).  
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Fig. 1. ABCD diagnostic criteria 
The presentation of newly formed or preexisting lesion is of great importance in early 
detection of melanoma; therefore, the letter E, which stands for Evolving, has been added to 
the  ABCD system. The introduction of ABCD criteria has drastically increased the number 
of melanoma diagnosed in its early, curable stage, without ulceration and with lower 
Breslow thickness (Rigel et al., 2010). Because of its complexity, Glasgow 7-point checklist 
(MacKie, 1990) is rarely used, contrary to Ugly Duckling Sign. This method is used to mark 
the nevus that deviate from surrounding lesions and require further examination for 
suspected malignancy (Scope et al., 2008).  
3.1 Skin self-examination 
The method of skin self-examination should be performed by whole population, especially 
individuals that are at higher risk for melanoma developing. Melanomas are most often 
detected by the patients themselves (Rigel et al., 2010). Patients who performed skin self-
examination have thinner melanoma than those who did not practice this approach (Pollitt 
et al., 2009). In addition to the good knowledge of the criteria for melanoma diagnosis by 
gynecologists and obstetricians, it is of great importance to perform regular skin self-
examination during pregnancy.   
3.2 Problems in pregnancy 
Pregnancy triggers a number of physiological changes, skin pigmentation is intensified, and 
nevi often became darker and bigger (Lens, 2008). These changes complicate the 
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establishment of melanoma diagnosis in pregnancy and physician in charge of a pregnant 
woman should not assign changed nevus only to physiology mechanisms in pregnancy. 
Each change of existing or appearance of new nevus should be followed carefully by 
gynecologist at each patient visit and biopsy should be indicated in case of each suspected 
lesion. A number of studies report that women diagnosed with melanoma during 
pregnancy present thicker tumors (Lens et al., 2004, MacKie et al., 1991, Travers et al., 1995.). 
In Lens study tumor tickness was 1.28 mm in pregnant and 1.07 mm in non-pregnant 
patients. Same observation was made by Travers et al. (2.28mm vs 1.22 mm). The authors 
explain this by the impact of hormones and growth factors, and delayed diagnosis 
compared to general population (Lens et al., 2004). Tumor tickness was independent factor 
for survival, but once tumor tickness was controlled for survival rate was the same in 
pregnant and non-pregnant patients.  
3.3 Excision and pathological examination 
Final diagnosis of melanoma is based on excisional biopsy and histopathology analysis. 
Each lesion suspected for melanoma should be completely removed with free margins. 
Lidocaine should be used as local anesthetic in pregnant women; epinephrine, usually 
used for better control hemostasis and prolongation of lidocaine effect, is not 
recommended because it belongs to group C according to Food and Drug Administration 
(Lawrence, 1996). A clinician has to provide pathologist with all relevant information 
about the patient; these information should include: the history of melanoma appearance 
among the family, the size and the location of excised lesion and  its morphological 
characteristics. Pathological report should include: the type of melanoma, dimesions, 
status of the margins, disease stage according to Breslow and Clarke, the existence of 
ulceration, presence of vascular and/or lymphatic invasion, mitotic index, and the 
growing phase (Lens, 2008). 
4. Staging 
Staging system used for melanoma is based on Union Internationale Contre la 
Cancer/American Joint Committee on Cancer Staging (UICC.AJCC) guidelines (Balch et al., 
2009) (Table 1 and Table 2.). Melanoma staging implies the use of histopathological 
procedures for measuring the depth of tumor invasion (Breslow thickness), sentinel node, 
radiology and nuclear medicine procedures. Some of those procedures are contraindicated 
in pregnancy.   
4.1 Sentinel node 
No locoregional recurrence will occur after local excision without lymphadenectomy in 
about 80% to 85% of patients with melanomas less than 4 mm thick (Breslow thickness). 
However, the rest of 15% to 20% of patients will experience locoregional recurrence 
(Hoekstra, 2008). In order to improve these results a number of authors have tried to 
routinely perform lymphadenectomy after the excision of primary tumor. Sim et al. (Sim et 
al., 1986) analyzed the survival of 171 patients with localized malignant melanoma; they 
preformed an early lymphadenectomy, delayed lymphadenectomy, or no 
lymphadenectomy at all. No statistically significant difference was found in either 
metastasis-free survival (MFS) or overall survival (OS). Cacscinelli et al. (Cascinelli et al., 
1998) examined 255 patients with melanoma located on the trunk and thicker than 1.5 mm. 
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They found no statistically significant difference in survival between patients with early 
lymphadenectomy and patients with lymphadenectomy performed after the diagnosis of 
lymph node metastases. Balch et al. (Balch et al, 1996) obtained similar results in comparing 
early lymphadenectomy with only follow-up. However, their extensive study showed 
certain benefits of lymphadenectomy in case of patients under 60 year of age and those with 
tumor thickness of 1 mm to 2 mm and no ulceration. Although no statistically significant 
difference was confirmed, the results of the above-mentioned studies show clearly that there 
are benefits from early lymphadenectomy for some patients. In 1992, Morton et al. 
developed the method of sentinel node biopsy (Morton et al., 1992). This technique combine 
99mTc and blue dye for mapping of affected lymph nodes. When metastases are confirmed 
by this method, surgeon perform complete lymph node resection in that area. Gershenwald 
(Gershenwald et al., 1999) and de Vries (de Vries et al., 2005) in their studies have pointed to 
the importance of sentinel node biopsy in the prognosis of melanoma patients. In addition, 
Morton (Morton et al., 2006) reports the results of Multicenter Selective Lymphadenectomy 
Trial I (MSLT I) regarding the sentinel node biopsy in patients with medium thick 
melanoma of (1.2 mm to 3.5 mm); they show better 5-year survival in patients with early 
lymphadenectomy than in case of patients with lymphadenectomy after confirmation of 
metastases development (72.3% vs. 52.4%, p=0.04). Beside, limphoedemas were more 
frequent in patients with delayed lymphadenectomy ( 20.4 vs 12.4%, p= 0,04) (Faries et al., 
2010) After all these results, sentinel node biopsy has become a standard in the treatment of 
melanoma (Valsecchi et al., 2011; Balch et al., 2009; Dummer et al., 2008). 
 
 
Table 1. UICC/AJCC TNM staging system 
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Table 2. UICC/AJCC TNM staging system 
4.1.1 Sentinel node mapping during pregnancy 
In spite of being a standard treatment in large healthcare centers sentinel node biopsy has 
generated a considerably controversy in case of pregnant patients. Because blue dye is 
contraindicated in pregnant women and 99mTc is a radioactive some surgeons avoid this 
procedure (Squatrito & Harlow, 2008). The results of at least five studies examined safety of 
the procedure for fetus in pregnant patients affected with melanoma or breast cancer. 
Gentilini et al. (Gentilini et al., 2004) have indirectly estimated the possible fetus exposure 
after application of radiopharmaceutical and its distribution in 26 premenopausal 
nonpregnant patients. They concluded that fetus exposure would be minimal and therefore 
the procedure could be safe for application in pregnant patients. Similar study has been 
performed by Keleher et al (Keleher  et al., 2004). Mondi et al. (Mondi et al., 2007) presented 
the first report on sentinel node biopsy during pregnancy. The procedure has been 
performed in nine pregnant patients – six patients with melanoma and three with breast 
cancer. All patients had delivery at term and there were no harms for fetus. A retrospective 
study conducted in H. Lee Moffitt Cancer Center, Tampa, Florida, USA (Mondi et al., 2007) 
analyse the results of sentinel node biopsy in 5,563 breast cancer patients. Ten of these 
patients were pregnant. Median duration of pregnancy was 15.8 weeks. Nine patients 
delivered a healthy child and one patient had intentional abortion. Another study was 
performed by Gentilini et al and its results were published last year (Gentilini et al., 2010). 
The study covered sentinel node biopsy in breast cancer patients applying 
radiophramaceutical only. Eleven of 12 patients delivered a healthy baby and in case of one 
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baby, ventricular septal defect was operated in the third month of pregnancy. Small number 
of patients, the fact that most patients had a breast cancer, results from indirect studies, and 
the studies in which blue dye was not applied refer that sentinel node biopsy has not been 
proved as a safety procedure yet. Pregnant patients must be warned to both benefits and 
possible harmfulness of this procedure.  
4.2 Radiology procedures in melanoma staging 
In case of low risk melanoma (tumor thickness less than 1 mm), detailed physical 
examination is enough and no further radiological procedures are required (Dummer et al., 
2008). In patients with locally advanced disease and lymph node involvement, optimal 
staging is indicated because of the probability for detection of distant metastases (Hoekstra, 
2008; Dummer et al., 2008). It is important to identify solitary operable metastases, which 
increase the chances for cure (Wasif et al., 2011). Ultrasound examination of abdomen and 
chest X ray are preferable in pregnancy because fetal exposure is minimal (Orecchia et al., 
2008). CT scan should be avoided in pregnant patients because of higher radiation doses. If 
ultrasound and X ray examination reveal suspected metastases that may have effects to 
further treatment course, CT scan may be used with strict respect of all procedures for fetus 
protection. Additional imaging examination with contrast medium should be avoided and 
low-dose protocols and minimal number of slices should be used (Orecchia et al., 2008). 
Magnetic resonance imaging may replace X-ray based techniques, but it is contraindicate in 
the first trimester (Campbell FA & Campbell C, 2006).  
4.3 Nuclear medicine procedures 
The use of positron-emission tomography (PET/CT) may change the stage of the disease 
and thus the change in treatment decision-making (Bastiaannet et al., 2006 a). Standard 
uptake value is a good prognostic factor of the recurrence in melanoma patients 
(Bastiaannet et al., 2006 b). On the other hand, PET/CT fails to detect distant metastases 
within the initial staging of patients with positive sentinel node biopsy (Wagner et al., 2011). 
Because PET/CT examination is contraindicated during pregnancy, it will not be discussed 
in this chapter.  
5. Prognosis 
The above chapters deal with the impact of earlier pregnancies and reproductive parameters 
to the development of malignant melanoma. This chapter presents studies that demonstrate 
the impact of pregnancy to treatment outcome and occurrence of transplancental metastasis 
5.1 Impact of pregnancy to melanoma prognosis 
From the ‘50s of the last century to present time, there have been many studies of the impact 
of pregnancy to melanoma prognosis. Most of these studies and meta-analyses show that 
malignant melanoma in pregnancy has no influence on patients survival. However, because 
the conclusions of these studies are inconsistent, it is still unclear whether pregnancy has 
impact to rapid tumor growth, more rapid occurrence of metastases, and poorer survival of 
patients (Sampson et al., 1998; Karagas et al., 2002).  From the first report on this issue, 
which was published in 1951 (Pack & Scharnagel , 1983), up to the ‘80s of the last century 
almost all studies demonstrate poorer survival rate from melanoma diagnose during 
pregnancy (Pack et al., 1951; Sutherland et al., 1983; Trapeznikov et al., 1987; Reintgen et al., 
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1085; McManamny et al., 1989; Wong et al., 1989; Slingluff et al., 1990; MacKie et al., 1991; 
O’Meara et al., 2005; Katsambas et al., 1996; Lazovich et al., 2010; Osterlind et al., 1988; Smith 
MA et al., 1998;  Shiu et al., 1976;  Houghton et al., 1981). These findings were mostly the 
consequence of diagnosing tumors in their higher stages during the pregnancy than in case 
of tumor diagnosis in nonpregnant women of the same age (Shiu et al., 1976; Houghton  et 
al., 1981; Landthaler & Braun-Falco, 1985), and frequent appearance of trunk melanoma 
(Houghton  et al., 1981). The first study that demonstrated no difference inthe overall 
survival rate was the one published by Wong et al. in 1989 (Wong et al., 1989). The authors 
compared the survival of 66 pregnant patients in stage I melanoma with 619 nonpregnant 
patients of the same age and found no difference in the 5-year survival.  In the study of 
Slingluff et al. (Slingluff et al., 1990) there was no difference in the survival time, but 
pregnant patients were presented with a larger number of involved lymph nodes (39% 
versus 26%, p=0.053) at diagnosis, lymph node metastases appeared in shorter interval after 
the diagnosis of stage I disease (p=0.021), and shorter disease free survival (DFS). The results 
of following studies have not reported difference in survival among pregnant patients 
(MacKie et al., 1991; Stein et al., 1990; Driscoll et al., 1993; Travers et al., 1995; Grin et al., 
1996; Daryanani et al., 2003), but in some a caution has been stressed to the diagnosis of 
thicker melanoma in pregnancy (MacKie et al., 1991; Travers et al., 1995). In already 
mentioned Lens et al. study (Lens et al., 2004) (Figure 2.), the results of investigate cohort of 
5,533 women (185 of them were pregnant) showed no difference in survival time between 
pregnant patients and general population with melanoma diagnosis. 
 
 
Fig. 2. Kaplan-Meier curve of the survival in pregnant patients with melanoma compared 
women in generative period (Lens et al., 2004) 
Another influential study is a meta-analysis by Karagas et al. (Karagas et al., 2006), which 
include results obtained in ten case-control studies. Their analysis also did not give evidence 
for the survival difference between pregnant and nonpregnant melanoma patients. After 
this study, the general opinion is that there is no difference in the survival between these 
www.intechopen.com
 
Advances in Malignant Melanoma – Clinical and Research Perspectives 
 
86
two patient groups. Yet, the last study that was conducted with a smaller group of patients 
gave opposite results (Miller et al., 2010)  and points out that not all issues in this sphere has 
been cleared up.  
5.2 Transplancental metastases and risk for fetus 
The occurrence of transplancental metastases in fetus is rare and when it occurs, the most 
common neoplasm is melanoma. Sporadic case reports can be found in current literature. 
The study, which particularly dealt with this phenomenon in melanoma, was conducted by 
Alexander et al. They analyzed MEDLINE database for the period 1966-2002 and found 87 
patients with placental metastases. Twenty-seven (31%) of these patients were diagnosed 
with metastatic melanoma and the rest of cases were breast and lung cancer, leukemia, and 
lymphoma. The involvement of fetus was found in six of 27 patients with placental 
metastases from melanoma.  Five of six newborn infants died. Because occurrence of 
melanoma in newborn infant is rare, no diagnostic standards exist. Some recommendations 
regarding the follow-up include complete skin examination, abdominal ultrasound, and 
screening for melanocytic proteins in urine (Alexander et al., 2003).  
5.3 Pregnancy after treatment of melanoma 
Contrary to the studies, that analyzed the impact of pregnancy to the treatment outcome of 
melanoma, the results of the studies that analyse the safety of pregnancy after melanoma 
diagnosis and treatment are more consistent. The results of all studies show that pregnancy 
after the treatment of melanoma is safe (Lens et al., 2004; Sutherland et al., 1983; Reintgen et 
al., 1985; Wong et al., 1989; MacKie et al., 1991; 71 28, Driscoll et al., 1993; o’Meara et al., 
2005; Driscoll & Grant-Kels, 2008). The risk of disease recurrence is mainly associated with 
the stage of the disease before the diagnosis and thus the opinion that the patient’s decision 
regarding the pregnancy should be based on the level of that risk (MacKie et al., 1991). There 
are authors that advice patients to avoid pregnancy during first two or three years after the 
treatment of melanoma (Lens st al., 2004, McManamny et al., 1989). Also, there is a report of 
successful pregnancy with no disease recurrence after the treatment of metastatic melanoma 
(Nikolin et al., 2005). 
6. Treatment 
Treatment of melanoma in pregnancy does not greatly differ from the treatment of 
melanoma in general population. However, certain problems such as somewhat more 
difficult inguinal lymphadenectomy in late pregnancy, as well as the application of some 
teratogenic medications, complicate the optimal treatment of pregnant women. 
6.1 Surgical treatment 
6.1.1 Excision of primary lesion 
More than hundred years ago, it was observed that the skin tumors spread in a star-like 
shape and that malignant cells exist even a few centimeters away from the visible tumor 
margins. However, many years later, it was proved that the probability of the surrounding 
spread depends on the size of the primary tumor. Initially, for all melanomas, regardless the 
tumor size, a technique that included 5 cm width of healthy tissue around the tumor was 
applied. With this kind of surgery, skin grafts were transplanted for most of the operations 
(Brady et al., 2009). After that, a large number of studies were performed, which proved that 
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for tumors of smaller size, it is not necessary for the margin to be so wide. Today’s 
recommendation of the sufficient margin for in situ melanomas is 0.5 cm, for those with the 
Breslow thickness less than 2 mm, it is 1 cm, while larger melanomas require the margin of 
more than 2 cm. In an early stage of the disease, there are no specificities related to 
pregnancy. If it is not possible to achieve a sufficiently wide excision, it is possible to use a 
skin graft, while the transfers of any deeper tissues are not recommendable because they 
postpone diagnosis of a local relapse (Hoekstra, 2008). Sentinel node biopsy is described 
earlier in this chapter.  
6.1.2 Regional lymphadenectomy 
Patients with, clinically observed, enlarged regional lymph nodes without any evidence of 
distant metastases, should be treated with regional lymphadenectomy. In some specific 
cases of enlarged lymph nodes, prior to this procedure, a fine needle aspiration should be 
performed (FNA) (Brady et al., 2009). In patients where lymph nodes are not enlarged, the 
performance of lymphadenectomy depends on the results of sentinel node biopsy, which is 
today a standard in melanoma staging (Valsecchi et al., 2011; Balch et al., 2009; Dummer et 
al., 2008). After a positive sentinel node biopsy, a regional lymphadenectomy is performed 
(Brady et al., 2009). This procedure may be more difficult due to pregnancy if it is a group of 
deep groin and loin lymph nodes. In case of late pregnancy, it is allowed to postpone 
lymphadenectomy after the childbirth (Hoekstra, 2008).  
6.1.3 Ocular melanoma 
Ocular melanoma mostly occurs in choroidea, although it may occur in the iris or cilliary 
body as well. When less than 3 mm, it usually does not have any symptoms, although, as 
the tumor grows, the patient notices a brown or a yellow spot in his visual field. In certain 
number of cases, melanoma causes an increase of intraocular pressure, and sometimes pain 
(Grgic et al., 2009). As an eye does not have any lymphatic vessels, melanoma does not have 
lymphogenous metastases, surgical postulates for cutaneous melanomas could not be 
applied. Some small and peripheral lesions can be excised with minimal loss of vision. Such 
melanomas can also be treated with the laser photocoagulation, transpupillary 
thermotherapy, and radiotherapy. However, the radiotherapy possibilities in pregnancy are 
limited. In the largest number of cases, it is necessary to perform enucleation, and 
sometimes the exenteration of the orbit. Besides that, the COMSG randomized study 
showed that implantation of the radioactive gold plaque behind the tumor, gives survival 
results similar to enucleation, with eye preservation, but again, there are no experiences 
with this method during the pregnancy (Brady et al., 2009; Grgic et al., 2009).  
6.1.4 Surgery of locoregional recurrences  
Locoregional metastases (satellite metastases, in-transit metastases) represent the recurrence 
of melanoma in the area between the primary lesion and the local lymph nodes. They are 
the consequence of intralymphatic spread outside the excision area (Heenan & Ghaznawie, 
1999). It is necessary to treat them like thick primary melanoma, because in this way the 
patient could be cured. Nevertheless, such treatment is not always possible and it depends 
on the number, location, and size of the lesions. The treatment is directed towards excision 
with healthy margins, while the amputation of the extremity is not indicated, because it 
does not increase survival. Besides, it is possible to treat small lesions with laser ablation 
(Testori et al., 2009). Certain studies proved successful the treatment with isolated extremity 
www.intechopen.com
 
Advances in Malignant Melanoma – Clinical and Research Perspectives 
 
88
perfusion by melphalan and tumor necrosis factor ┙ (TNF┙) (Lienard et al., 1992; 
Grunhagen et al., 2004). However, as there is no experience in this procedure during 
pregnancy, some authors consider it contraindicated for the time being (Hoekstra, 2008), 
while others consider that in specific situations it can be applied due to minimal systemic 
absorption (Dummer et al., 2008).  
6.1.5 Surgery in stage IV disease 
Some studies showed that resection of single metastasis is related to the prolonged survival 
(Sarnaik et al., 2007; McLoughlin et al., 2008). However, there are no studies that compared 
surgical and conservative treatment of single metastasis. Most of authors advise metastasis 
resection in such a case (Testori et al., 2009). This recommendation is surely the safest and 
the most efficient in pregnant patients.  
6.2 Radiotherapy 
Because surgical treatment of cutaneous melanoma achieves good results, the use 
radiotherapy in the treatment of primary melanoma does not have its place (Testori et al., 
2009). Vontgama et al. showed certain efficacy of radiotherapy in desmoplastic melanoma, 
when the clean margins after surgery could not be achieved (Vongtama et al., 2003). On the 
other hand, radiotherapy of the primary melanoma of the nasal cavity and the paranasal 
sinuses is successfully applied because melanoma of this region has tendency of more often 
local than systemic relapse and it is sometimes very difficult to access this region for 
complete surgery (Testori et al., 2009). Furthermore, seems like postoperative therapy gives 
better results than surgery alone in melanoma of this region (Stevens & mcKay, 2006; Kirova 
et al., 1999). However, there are no randomized studies, which could support this. 
Depending on the number, size and localization of the lymph nodes, local relapse after 
lymphadenectomy is found in 20%-50% of cases (Calabro et al., 1989). Since such relapse is 
very difficult for treatment, there were attempts to obtain better results with postoperative 
radiotherapy. Although some phase II studies showed certain efficacy (Testori et al., 2009), 
the only randomized study did not show any difference, neither in DFS, nor in OS (Creagan 
et al., 1978). Radiotherapy in metastatic melanoma is especially significant for symptoms 
palliation, primarely of pain due to bone metastases (Testori et al., 2009). In pregnancy, such 
treatment would be theoretically possible if the metastases are not located in the area of 
lower thoraces and lumbar vertebrae, which shall be discussed later. The greatest 
significance of radiotherapy in metastatic melanoma is the treatment of brain metastases. 
CNS metastases occur in 10%-40% of melanoma patients (Douglas & Margolin, 2002). A 
median survival without treatment is about 1 month. A whole brain radiotherapy treatment 
(WBRT) in 60%-70% of patients reduces the symptoms, improves neurological status, and 
prolongs survival up to 6 months (Patchell, 2003). Furthermore, in solitary metastases, 
WBRT after surgery prolongs survival when compared to surgery alone (Tarhini & 
Agarwala, 2004). In addition, stereotactic radiosurgery (e.g. gamma knife), irradiation by 
linear accelerator (Linac) and surgery, have equal results in treatment of one operable 
metastasis (Grob et la., 1998).  
6.2.1 Radiotherapy of melanoma in pregnancy 
Due to risk of death or heavy malformation of the fetus, radiotherapy in pregnancy was the 
subject of controversies due to the necessary balance between the benefits for the mother 
and the harmful effect to the fetus (Kal & Struikmans, 2005). Some authors postpone 
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irradiation therapy of breast carcinoma during the pregnancy (Pavlidis, 2002; Gwyn 2000), 
while the others recommend the termination of pregnancy if the doses received by the fetus 
are larger than 0.05-0.1 Gy (Greer et al., 1997). There is no doubt that high X-ray doses are 
extremely harmful for the fetus, but more current approaches show that irradiation therapy 
can be safely applied in most of the cases (Kal & Struikmans, 2005). During the earliest 
pregnancy, doses above 0.1-0.2 Gy lead to the death of the embryo; in weeks 2 to 8 of 
organogenesis they may cause heavy anomalies, while in the later period of CNS 
development hinder development of intelligence and cause consequential mental 
retardation consequentially. The occurrence of neoplasms in children is more frequent to 
some extent (Kal & Struikmans, 2005). Regardless these data, the greatest number of 
irradiation therapies outside the pelvis can be safely applied. The first prerequisite for this is 
a careful planning, a properly functioning device that does not dissipate irradiation and an 
adequate protection of abdomen and pelvis of a pregnant woman. Van der Giesen et al. 
calculated the doses for breast cancer irradiation, which are received by the fetus during the 
standard therapy of 50 Gy (Van der Giessen 1997). Namely, the dosage was 0.03 Gy in week 
8, 0.2 Gy in week 24, and 1.43 Gy in week 36 because the fetus is larger and thus closer to the 
irradiation source. Several cases of births of healthy children after the irradiation therapy of 
breast carcinoma are reported. A large number of series of irradiation therapy of 
supradiaphragmally localized Hodgkin lymphoma in pregnant women, who gave birth to 
healthy children, is also presented in literature (Zucali et al., 1981; Mazonakis et al., 2003; 
Lishner et al., 1992). Fetal dose in brain irradiation with 54 Gy at Varian accelerator is about 
0.22 Gy, and even without any shielding, the fetus dosage almost never exceeds 0.1 Gy 
(Haba et al., 2004; Mazonakis et al., 1999). There was one case of a pregnant patient who 
underwent a gamma-knife treatment due to melanoma metastases without any 
consequences upon her child (Yu et al., 2003). A case of a pregnant patient irradiated with 66 
Gy for head and neck tumor was also presented (Podgorsak et al., 1999). In melanoma 
treatment during pregnancy, the benefits and the harmfulness of the radiotherapeutic 
treatment should be properly balanced. A possible irradiation of some distant regions 
postoperatively, due to positive margins, could be taken into consideration. Sinusal 
melanoma irradiation was proved useful and it is safe for the fetus. Adjuvant irradiation 
after lymphadenectomy proved no benefit in a randomized study (Creagan et al., 1978), so it 
should be avoided in pregnancy. A specific question is when to irradiate a pregnant patient 
with metastatic melanoma. In our opinion, palliative irradiation of the lower thoracic and 
lumbar vertebrae should be avoided. In the case of brain metastases, the fetus receives a 
minimal dosage of irradiation, which sometimes could be useful for patient’s prolongation 
of life and ending of pregnancy in a due term. Indications for pregnancy termination in 
irradiated patients, who were not aware of being pregnant at the moment of irradiation, are 
the doses over 0.5 Gy upon the fetus, because that would almost certainly lead to fetus 
malformation, while the doses of 0.2 Gy bear the risk of mental retardation of a child (Kal & 
Struikmans, 2005).  
6.3 Systemic treatment 
6.3.1 Adjuvant therapy 
Adjuvant treatment, for stage II/III melanoma is a subject of controversy. The reason is a 
large number of studies, which tested various agents, chemotherapy, immunomodulators, 
and therapeutic vaccines with more or less success (Eggermont et al., 2009). Although 
Wheatley et al. (Wheatley et al., 2007) and Mocellina et al. (Mocellina et al., 2010), 
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demonstrated a prolonged DFS and OS in meta-analyses of interferon ┙ (IFN┙) studies, such 
therapy did not become a standard because neither the optimal dose of IFN┙ nor the 
optimal duration of treatment is still known. It is considered that the control arm, used in 
clinical trials, should be just follow up after the complete surgery (Wheatley et al., 2007). The 
EORTC 18991 study, in which high doses of a pegylated IFN┙ were used, demonstrated a 
prolonged DFS (p=0.01), but without any effect either to distant-metastasis-free survival 
(DMFS), or to OS. The greatest benefit was observed in patients with micrometastases 
detected by the sentinel node biopsy, while the patients with palpable lymph nodes did not 
have any benefits (Eggermont et al., 2008). Several studies with small doses of IFN┙ showed 
the effect to DFS (Grob et al., 1998;  Pehamberger et al., 1998; Cameron et al., 2001; Kirkwood 
et al., 2000; Hancock et al., 2004), of which, only one showed significant importance for OS 
(Grob et al., 1998). On the other hand, the WHO-16 study, which tested low doses of IFN┙ in 
duration of 3 years in patients in stadiums IIIB and IIIC, did not show any significant effect 
to DFS or OS (Cascinelli et al., 2001). Some other drugs were tested in combination with 
IFN┙, although dacarbazine (Garbe et al., 2008), Melacine (Mitchell et al., 2007), IL-2 
(Hauschild et al., 2003), or isotretinoin (Richtig et al., 2005) did not show any difference in 
comparison to IFN┙ alone. As the results of various studies are very different, there is a 
question if an adjuvant therapy should be applied, especially in the case of a pregnant 
patient. On the one side toxicity and a possible teratogenicity of drugs that would be used 
are opposed to higher aggressiveness of melanoma in pregnancy, observed in several 
studies (Shiu et al., 1976; 73 36; Landthaler & Braun-Falco, 1985). There are no sufficient data 
on IFN┙ safety during pregnancy. One study of a smaller scope did not observe any defects 
in the fetuses after their birth although the patients were treated with IFN┙ (Egberts et al., 
2006). However, IFN┙ was used during pregnancy in some other indications. In 14 patients 
with immune thrombocytopenia, 2 of which were in their first trimester, there were no 
observed changes in the fetus (Vantroyen & Vanstraelen,  2002). However, in the study 
where the patients were treated from a chronic hepatitis or myeloproliferative syndrome (6 
were in the first trimester), there were 4 cases of a premature childbirth and 6 cases of 
intrauterine growth retardation (Hiratsuka et al., 2002).  
6.3.2 Metastatic disease 
Median 5-year survival of the melanoma patients in stage IV is less than 5% (Rigel et al., 
1996). Until two years ago, there was no drug that prolongs survival in patients with distant 
melanoma metastases. For the purpose of palliation, the most frequently used drug was 
dacarbazine with small RR and the median survival, not longer than the natural survival 
duration in melanoma patients. A large number of different drugs, alone or in combination 
with dacarbazine did not show any difference in relation to RR, DFS, or OS (Brady et al., 
2009). Thus, a major question rises, whether to administer dacarbazine to pregnant patients 
with a metastatic disease, having in mind the risk, which it carries for the fetus and its 
minimal benefit for the patient. However, some patients demand treatment and some 
physicians think that it would be unethical if they do not try a cytotoxic therapy. There are 
certain experiences in administration of dacarbazine-based therapy in pregnancy. Thirty-six 
patients were administered dacarbazine during pregnancy, 8 of them during their first and 
28 of them during their second and third trimesters. Malformations were observed in two 
fetuses exposed to chemotherapy during the first trimester. In one fetus, a micorophthalmus 
with secondary heavy hypermetropia was observed, while the other experienced floating 
thumb malformation. In administration of chemotherapy after the first trimester, one fetus 
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died in utero, while in the other one a syndactyly was observed. Other fetuses were born 
without any malformations and after a short follow up of 14 months, they were still healthy. 
In the last two cases, a polychemotherapy was used (Pages et al., 2010). Intensive research in 
metastatic melanoma treatment achieved significant results in the past few years. Several 
new drugs proved to be better than standard dacarbazine therapy. Immunotherapy based 
treatment has been tested for decades and is used in melanoma treatment. Ipilimumab and 
tremelimumab are monoclonal antibodies, which bind to cytotoxic T-lymphocyte-associated 
antigen (CTLA4). Under natural conditions, this receptor binds to receptor B7 at the antigen 
presenting cells and thus, prevents connecting of molecule CD28 that binds to this receptor 
and conditions the T-cells activation. Under normal conditions, this reaction induces self-
tolerance. By blockage of CTLA4 receptors, an undisturbed connecting of CD28 and B7 
occurs, and induction of antitumor effect of T-cells to melanoma cells (Schadendorf et al., 
2009). In the largest study published until now, median overall survival was 10.1 months 
(Hodi et al., 2010). Some other immunomodular drugs were tested in metastatic melanoma: 
human anti-CD137 antibody, anti-integrin antibodies volociximab and etaracizumab, as well 
as various vaccines: MAGE-3, dendritic, peptide vaccines, etc. (Schadendorf et al., 2009). 
These agents are mostly in phase I or II of clinical trials and the results are expected in the 
following period. Cell signal transition inhibitors take very important role in oncology in the 
last decade. RAF/RAS/MEK signaling pathway is very important in melanoma because it 
participates in proliferation induction and apoptosis inhibition. A large number of inhibitors 
of this signaling pathway are in different phase of clinical trials: sorafenib, AZD6244, 
tipifarnib, (Hersey et al., 2009). A most remarkable result in treatment was achieved with 
direct B-Raf inhibitor PLX4032 (Flaherty et al., 2010). In the phase I/II study 32 patients with 
V600 BRAF mutation, 24 partial and two complete remissions were achieved, with DFS of 
over 7 months. Besides that, the inhibitors of some other signaling pathways are also 
intensively tested. They include various inhibitors like tyrosine kinase, PI3K, Akt, mTOR, 
Stat3 inhibitors, and many other agents (Hersey et al., 2009). Since these drugs are mostly 
present in clinical trials, and in most of the trials, pregnancy is an exclusion criteria, there is 
no experience in treatment of childbearing women. A drug, which would most likely be the 
first to enter regular clinical practice, ipilimumab, causes autoimmunity (Schadendorf et al., 
2009), which may be expressed through a syndrome, similar to lupus or antiphospholipid 
syndrome, which may be fatal both for the fetus and the mother. Experience with imatinib 
in chronic myeloid leukemia in pregnant patients shows that imatinib is teratogenous 
(Apperley, 2009). Nevertheless, there was a case where the patient was treated with 
dasatinib and two cases of treatment with nilotinib where healthy children were born 
(Conchon et al., 2010;  Conchon et al., 2009). 
7. Future remarks 
Since etiology and the connection between the hormones, pregnancy and melanoma is not 
entirely clarified, and the results of metastatic melanoma treatment are poor, there are still 
many unanswered questions related to the etiology, but also to the treatment of melanoma. 
Huu et al. (Huu et al., 2009) tested the presence of fetal cells in human melanomas, 
diagnosed during pregnancy. They found that the fetal cells were present in 63% of 
melanoma, 12% of nevus during pregnancy and 0% in healthy skin. Since fetal cells are 
capable of developing in various tissues and since they precipitate angiogenesis, it remains 
to be seen, whether they have any, and what their role in melanoma development during 
pregnancy is. Estrogen receptors, their relationship, and the possibility of the hormone 
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therapy in melanoma shall also be the subject of further research. Namely, relationship 
between ER┙ and ER┚ is probably of the key significance for the response to the hormone 
therapy (de Giorgi et al., 2011). Efficacy and safety of the new drugs’ administration in 
pregnancy is still to be seen.   
8. References  
Abbasi NR, Shaw HM, Rigel DS, et al.  (2004) Early diagnosis of cutaneous melanoma: 
revisiting the ABCD criteria. JAMA. 2004; 292:2771-2776 
Alexander A, Samlowski WE, Grossman D, et al. (2003) Metastatic melanoma in pregnancy: 
risk of transplacental metastases in the infant. J Clin Oncol 2003; 21(11): 2179–2186 
Anonymous (2003) Stat bite: incidence of and mortality from melanoma of the skin, 1975–2000. 
J Natl Cancer Inst 2003; 95(13): 933 
Antypas C, Sandilos P, Kouvaris J, et al. (1998) Fetal dose evaluation during breast cancer 
radiotherapy. Int J Radiat Oncol Biol Phys 1998; 40: 995–99. 
Apperley J. (2009)  Issues of imatinib and pregnancy outcome J Natl Compr Canc Netw 2009; 
7(10): 1050-8 
Balch CM, Gershenwald JE, Soong SJ, et al. (2009) Final version of 2009 AJCC melanoma 
staging and classification. J Clin Oncol. 2009 Dec 20;27(36):6199-206 
Balch CM, Morton DL, Gershenwald JE, et al.(2009) Sentinel node biopsy and standard of care 
for melanoma.J Am Acad Dermatol. 2009 May;60(5):872-5 
Balch CM, Soong SJ, Bartolucci AA, et al.(1996) Efficacy of an elective regional lymph node 
dissection of 1 to 4 mm thick melanomas for patients 60 years of age and younger. 
Ann Surg 1996; 224: 255–263  
Bastiaannet E, Hoekstra OS, Oyen WJ, et al. (2006). Level of fluorodeoxyglucose uptake 
predicts risk for recurrence in melanoma patients presenting with lymph node 
metastases.Ann Surg Oncol. 2006 Jul;13(7):919-26 
Bastiaannet E, Oyen WJ, Meijer S, Hoekstra OS,et al. (2006). Impact of [18F]fluorodeoxyglucose 
positron emission tomography on surgical management of melanoma patients. Br J 
Surg. 2006 Feb;93(2):243-9 
Brady M, Kaushal A, Ko C. et al. (2009) Melanoma and other skin cancers In: 
CancerManagement: A Multidiciplinary Approach 12th Edition, Pazdur M, Wagman L, 
Camphausen K et al. CMP Healthcare Media LLC  
Calabro A, Singletary SE, Balch CM. (1989) Patterns of relapse in 1001 consecutive patients 
with melanoma nodal metastases. Arch Surg 1989; 124: 1051–1055. 
Cameron DA, Cornbleet MC, Mackie RM et al. (2001) Adjuvant interferon alpha 2b in high risk 
melanoma—the Scottish study. Br J Cancer 2001; 84: 1146–1149. 
Campbell FA, Campbell C. Magnetic resonance imaging for stage IV melanoma during 
pregnancy. (2006) Arch Dermatol 2006;142:393 
Cancer Research UK Malignant melanoma factsheet May 2006. Available at: 
www.info.cancerresearchuk.org. Accessed November 9, 2006 
Cascinelli N, Belli F, MacKie RM et al. (2001) Effect of long-term adjuvant therapy with 
interferon alpha-2a in patients with regional node metastases from cutaneous 
melanoma: a randomised trial. Lancet 2001; 358: 866–869. 
Cascinelli N, Morabito A, Santinami M, et al. (1998)  Immediate or delayed dissection of 
regional nodes in patients with melanoma of the trunk: a randomized trial. WHO 
Melanoma Programme. Lancet 1998; 351: 793–796 
www.intechopen.com
 
Melanoma During Pregnancy 
 
93 
Cochran AJ, Todd G, Hart DM, et al. (1982) Reaction of the leukocytes of melanoma patients 
and control donors, including pregnant women, with melanoma and fetus-derived 
materials. Cancer Immunol Immunother 1982; 14:78-81 
Colboum DS, Nathanson L, Belilos E (1989) Pregnancy and malignant melanoma. Semin Oncol 
1989; 16:377-387 
Conchon M, Sanabani SS, Bendit I, et al. (2009) Two successful pregnancies in a woman with 
chronic myeloid leukemia exposed to nilotinib during the first trimester od her 
second pregnancy: case study J Hematol Oncol 2009 Oct;2:42 
Conchon M, Sanabani SS, Serpa M, et al. (2010) Suucessful pregnancy and delivery in a patient 
with chronic myeloid leukemia while on dasatinib therapy Adv Hematol 2010 Epub 
Mar 7 
Creagan ET, Cupps RE, Ivins JC et al. (1978) Adjuvant radiation therapy for regional nodal 
metastases from malignant melanoma: a randomized, prospective study. Cancer 1978; 
42: 2206–2210. 
Daryanani D, Plukker JT, De Hullu JA,et al. (2003). Pregnancy and early-stage melanoma. 
Cancer 2003 May 1;97(9):2248-53 
de Giorgi V, Mavilia C, Massi D, et al (2009) Estrogen receptor  expression in cutaneous 
melanoma: A real-time reverse transcriptase-polymerase chain reaction and 
immunohistochemical study. Arch Dermatol 2009;145:30-36 
de Giorgi V, Gori A, Alfaioli B,et al. (2011) .Influence of sex hormones on melanoma. J Clin 
Oncol. 2011 Feb 1;29(4):e94-5 
de Vries M, Jager PL, Suurmeijer AJ, et al. (2005) .Sentinel lymph node biopsy for melanoma: 
prognostic value and disadvantages in 300 patients Ned Tijdschr Geneeskd. 2005 Aug 
13;149(33):1845-51 
Dillman RO, Vandermolen LA, Barth NM, et al. (1996) Malignant melanoma and pregnancy. 
West J Med 1996;164: 156–161 
Douglas JG, Margolin K. (2002) The treatment of brain metastases from malignant melanoma. 
Semin Oncol 2002; 29: 518–524. 
Driscoll MS, Grant-Kels JM. (2008) Melanoma and pregnancy. G Ital Dermatol Venereol. 2008 
Aug;143(4):251-7 
Driscoll MS, Grin-Jorgensen CM, Grant-Kels JM. (1993) Does pregnancy influence the 
prognosis of malignant melanoma?  J Am Acad Dermatol. 1993 Oct;29(4):619-30. 
Dummer R, Hauschild A, Jost L; (2008) ESMO Guidelines Working Group Cutaneous 
malignant melanoma: ESMO clinical recommendations for diagnosis, treatment and 
follow-up. Ann Oncol. 2008 May;19 Suppl 2:ii86-8. 
Durvasula R, Ahmed SM, Vashisht A, et al. (2002) Hormone replacement therapy and 
malignant melanoma: to prescribe or not to prescribe? Climacteric 2002; 5(2): 197–200 
Egberts F, Lischner S, Russo P, et al. (2006) Diagnostic and therapeutic procedures for 
management of melanoma during pregnancy: risks for the fetus? J Dtsch Dermatol 
Ges. 2006 Sep;4(9):717-20 
Eggermont AM, Suciu S, Santinami M et al. (2008) Adjuvant therapy with pegylated interferon 
alpha-2b versus observation alone in resected stage III melanoma: final results of 
EORTC 18991, a randomised phase III trial. Lancet 2008; 372: 117–126. 
Eggermont AM, Testori A, Marsden J, et al. (2009) Utility of adjuvant systemic therapy in 
melanoma.Ann Oncol. 2009 Aug;20 Suppl 6:vi30-4. 
Elwood JM, Coldman AJ (1978) Previous pregnancy and melanoma prognosis. Lancet 1978; 
2(8097): 1000–1001 
Faries MB, Thompson JF, Cochran A, et al. (2010) The impact on morbidity and length of stay 
of early versus delayed complete lymphadenectomy in melanoma: results of the 
www.intechopen.com
 
Advances in Malignant Melanoma – Clinical and Research Perspectives 
 
94
Multicenter Selective Lymphadenectomy Trial (I) Ann Surg Oncol. 2010 
Dec;17(12):3324-9 
Fisher D, Kwong L, Chin L (2008) Molecular Biology of Cutaneous Melanoma In De Vita, 
Hellman, Rosberg Cancer: Principle and Practice of Oncology LWW 2008: 1889-1897  
Flaherty K, Puzanov I, Kim K, et al. (2010) Inhibition of Mutated, Activated BRAF in Metastatic 
Melanoma N Engl J Med 2010; 363:809-819 
Friedman RJ, Rigel DS, Kopf AW (1985) Early detection of malignant melanoma: the role of 
physician examination and self-examination of the skin. CA Cancer J Clin 1985; 35: 
130–151 
Garbe C (1993) Pregnancy, hormone preparations and malignant melanoma Hautarzt 1993;44: 
347–352 
Garbe C, Radny P, Linse R et al. (2008) Adjuvant low-dose interferon {alpha}2a with or 
without dacarbazine compared with surgery alone: a prospective-randomized phase 
III DeCOG trial in melanoma patients with regional lymph node metastasis. Ann 
Oncol 2008; 19: 1195–1201. 
Gentilini O, Cremonesi M, Toesca A, et al. (2010) Sentinel lymph node biopsy in pregnant 
patients with breast cancer.Eur J Nucl Med Mol Imaging. 2010 Jan;37(1):78-83 
Gentilini O, Cremonesi M, Trifirò G, et al. (2004) Safety of sentinel node biopsy in pregnant 
patients with breast cancer.Ann Oncol. 2004 Sep;15(9):1348-51 
George PA, Fortner JG, Pack GT (1960) Melanoma with pregnancy. Cancer 1960; 13:854-859 
Gershenwald JE, Thompson W, Mansfield PF, et al. (1999) Multi-institutional melanoma 
lymphatic mapping experience: the prognostic value of sentinel lymph node status in 
612 stage I or II melanoma patients J Clin Oncol 1999 Mar;17(3):976-83 
Greer BE, Goff BA, Koh W. (1997) Cancer in the pregnant patient. In Hoskins WJ, Perez CA, 
Young RC, eds. Principles and practice of gynecologic oncology, 2nd edn. New York: 
Lippincott Raven, 1997: 463–70. 
Grgic Z, Oros A, Rasic D, Popovic L, Popovic M (2009) Ocular malignant melanoma in 
pregnancy: Is a happy ending possible? Arch Oncol 2009; 17: 83-85 
Grin CM, Driscoll MS, Grant-Kels JM (1996) Pregnancy and the prognosis of malignant 
melanoma  Semin Oncol. 1996 Dec;23(6):734-6. 
Grob JJ, Dreno B. de la Salmonie` re P et al.(1998) Randomised trial of interferon alpha- 2a as 
adjuvant therapy in resected primary melanoma thicker than 1.5 mm without 
clinically detectable node metastases. Lancet 1998; 351: 1905–1910.  
Grob JJ, Regis J, Laurans R et al. (1998) Radiosurgery without whole brain radiotherapy in 
melanoma brain metastases. Club de Cancerologie Cutanee. Eur J Cancer 1998; 34: 
1187–1192. 
Grunhagen DJ, Brunstein F, Graveland WJ et al. (2004) One hundred consecutive isolated limb 
perfusions with TNF-alpha and melphalan in melanoma patients with multiple in-
transit metastases. Ann Surg 2004; 240: 939–948. 
Gwyn KM, Theriault RL.(2000) Breast cancer during pregnancy. Curr Treat Options Oncol 2000; 
1: 239–43. 
Haba Y, Twyman N, Thomas SJ, et al. (2004) Radiotherapy for glioma during pregnancy: fetal 
dose estimates, risk assessment and clinical management. Clin Oncol (R Coll Radiol) 
2004; 16: 210–14. 
Hancock BW, Wheatley K, Harris S et al. (2004) Adjuvant interferon in high-risk melanoma: 
the AIM HIGH Study–United Kingdom Coordinating Committee on Cancer 
Research randomized study of adjuvant low-dose extended-duration interferon alfa-
2a in high-risk resected malignant melanoma. J Clin Oncol 2004; 22: 53–61. 
www.intechopen.com
 
Melanoma During Pregnancy 
 
95 
Hauschild A, Weichenthal M, Balda BR et al. (2003) Prospective randomized trial of interferon 
alfa-2b and interleukin-2 as adjuvant treatment for resected intermediate- and high-
risk primary melanoma without clinically detectable node metastasis. J Clin Oncol 
2003; 21: 2883–2888. 
Heenan PJ, Ghaznawie M. (1999) The pathogenesis of local recurrence of melanoma at the 
primary excision site. Br J Plast Surg 1999; 52: 209–213. 
Hersey P, Bastholt L, Charion-Sileni V, et al. (2009) Small molecules and targeted therpies in 
distant metastatic disease Ann Oncol 2009 Aug;20 Suppl 6: vi35-vi40 
Hiratsuka M, Minakami H, Koshizuka S, et al. (2002) Administration of interferon-alpha 
during pregnancy: effects on fetus. J Perinat Med 2002; 28: 372–376  
Hodi S, O'Day S, McDermott D, et al. (2010) Improved Survival with Ipilimumab in Patients 
with Metastatic Melanoma N Engl J Med 2010; 363:711-723 
Hoekstra HJ Melanoma during pregnancy: Therapeutic Management and Outcome In 
Surbone A., Peccatori F, Pavlidis N Cancer and Pregnancy Recent Results in Cancer 
Research  vol. 178; Springer 2008: 175-181 
Houghton AN, Flannery J, Viola MV  (1981) Malignant melanoma of the skin occurring during 
pregnancy. Cancer 1981; 48:407-410 
Huu SN, Oster M, Avril MF, et al. (2009) Fetal microchimeric calls participate in tumour 
angiogenesis in melanomas occuring during pregnanvy Am J Pathol 2009; 174 (2): 630-
7 
Jemal A, Siegel R, Xu J, et al. (2010) Cancer Statistics, 2010 CA Cancer J Clin 2010; 60:277-300   
Karagas MR, Stukel TA, Dykes J, et al. (2002) A pooled analysis of 10 case-control studies of 
melanoma and oral contraceptive use. Br J Cancer 2002; 86(7):1085–1092 
Karagas MR, Zens MS, Stukel TA, et al. (2006) Pregnancy history and incidence of melanoma 
in women: a pooled analysis. Cancer Causes Control 2006; 17(1): 11–1929.  
Kal H, Struikmans H (2005) Radiotherapy during pregnancy: fact and fiction Lancet Oncol 
2005;6:328-33 
Katsambas A, Nicolaidou E (1996) Cutaneous malignant melanoma and sun exposure. Recent 
developments in epidemiology. Arch Dermatol. 1996 Apr;132(4):444-50 
Lawrence C. (1996) Drug management in skin surgery. Drugs 1996;52:805-17. 
Keleher A, Wendt R, Delpassand E, et al. (2004) The safety of lymphatic mapping in pregnant 
breast cancer patients using Tc-99m sulfur colloid. Breast J 2004;10:492-5 
Landthaler M, Braun-Falco O. (1985) Malignant melanomas in pregnancy. Dtsch Med 
Wochenschr. 1985 Aug 30;110(35):1319-23 
Khera SY, Kiluk JV, Hasson DM, et al. (2008)  Pregnancy-associated breast cancer patient can 
safely undergo lymphatic mapping Breast J 2008; 14(3):250-4 
Kirkwood JM, Ibrahim JG, Sondak VK et al. (2000) High- and low-dose interferon alfa-2b in 
high-risk melanoma: first analysis of intergroup trial E1690/S9111/C9190. J Clin 
Oncol 2000; 18: 2444–2458. 
Kirova YM, Chen J, Rabarijaona LI et al. (1999) Radiotherapy as palliative treatment for 
metastatic melanoma. Melanoma Res 1999; 9: 611–613. 
Lazovich D, Vogel RI, Berwick M, et al (2010) Indoor tanning and risk of melanoma: A case-
control study in a highly exposed population. Cancer Epidemiol Biomarkers Prev 2010; 
19:1557-1568 
Lea  CS, Holly EA, Hartge P et al. (2007) Reproductive risk factors for cutaneous melanoma in 
woman: a case-control study Am J Epidemiol 2007; 165(5): 505-513 
Lens MB, Melanoma during pregnancy: epidemiology, diagnosis, staging, clinical picture In 
Surbone A., Peccatori F, Pavlidis N Cancer and Pregnancy Recent Results in Cancer 
Research  vol. 178; Springer 2008:165-174 
www.intechopen.com
 
Advances in Malignant Melanoma – Clinical and Research Perspectives 
 
96
Lens MB, Reiman T, Husain AF (2003) Use of tamoxifen in the treatment of malignant 
melanoma. Cancer 2003; 98:1355-1361 
Lens MB, Rosdahl I, Ahlbom A, et al. Effect of pregnancy on survival in women with 
cutaneous malignant melanoma. J Clin Oncol 2004; 22(21): 4369–4375 
Lienard D, Ewalenko P, Delmotte JJ et al. (1992) High-dose recombinant tumor necrosis factor 
alpha in combination with interferon gamma and melphalan in isolation perfusion of 
the limbs for melanoma and sarcoma. J Clin Oncol 1992; 10: 52–60. 
Lishner M, Zemlickis D, Degendorfer P, et al. (1992) Maternal and foetal outcome following 
Hodgkin’s disease in pregnancy. Br J Cancer 1992; 65: 114–17 
MacKie RM. (1990) Clinical recognition of early invasive malignant melanoma. BMJ. 
1990;301:1005-1006 
MacKie RM, Bufalino R, Morabito A, et al. (1991)  Lack of effect of pregnancy on outcome of 
melanoma—The World Health Organisation Melanoma Programme. Lancet 1991; 
337:653–655 
Matthiasen L, Berg G (1989) Malignant melanoma, the most common cancer type, first 
appearing during pregnancy. L臾artidningen 1989;86:2845–2848 
Mazonakis M, Damilakis J, Theoharopoulos N, et al. (1999) Brain radiotherapy during 
pregnancy: an analysis of conceptus dose using anthropomorphic phantoms. Br J 
Radiol 1999; 72: 274–78. 
Mazonakis M, Varveris H, Fasoulaki M, et al. (2003) Radiotherapy of Hodgkin’s disease in 
early pregnancy: embryo dose measurements. Radiother Oncol 2003; 66: 333–39. 
McLoughlin JM, Zager JS, Sondak VK, et al. (2008) Treatment options for limited or 
symptomatic metastatic melanoma. Cancer Control 2008; 15: 239–247. 
McManamny DS, Moss ALH, Pocock PV, et al. (1989) Melanoma and pregnancy: a long-term 
follow-up. Br J Obstet Gynaecol 1989; 96: 1419–1423 
Miller E, Barnea Y, Gur E, et al. (2010) Malignant melanoma and pregnancy: second thoughts. J 
Plast Reconstr Aesthet Surg. 2010 Jul;63(7):1163-8. 
Mitchell MS, Abrams J, Thompson JA et al. (2007) Randomized trial of an allogeneic melanoma 
lysate vaccine with low-dose interferon alfa-2b compared with highdose interferon 
alfa-2b for resected stage III cutaneous melanoma. J Clin Oncol 2007; 25: 2078–2085. 
Mocellin S, Pasquali S, Rossi D, et al. (2010) Interferon alpha adjuvant therapy in patients with 
high-risk melanoma: a systematic review and meta-analysis J Natl Cancer Inst 2010; 
102: 493-501120.  
Mondi MM, Cuenca RE, Ollila DW, et al. (2007) Sentinel lymph node biopsy during 
pregnancy: initial clinical experience. Ann Surg Oncol 2007;14 (1):218-21 
Morton DL, Thompson JF, Cochran AJ, et al. (2006) Sentinel-node biopsy or nodal observation 
in melanoma. N Engl J Med 2006; 355: 1307–1317 
Morton DL, Wen DR, Wong JH, et al. (1992) Technical details of intraoperative lymphatic 
mapping for early stage melanoma. Arch Surg 1992; 127: 392–399 
Ngu SL, Duval P, Collins C. (1992) Foetal radiation dose in radiotherapy for breast cancer. 
Australas Radiol 1992; 36: 321–22. 
Nikolin B, Sveljo O. (2005) Metastatic melanoma in pregnancy Arch Oncol 2005;13(1):31-4 
O’Meara AT, Cress R, Xing G, et al. (2005) Malignant melanoma in pregnancy. A population-
based evaluation. Cancer 2005; 103(6):1217–1226 
Orecchia R, Lucignani G, Tosi G Prenatal iradiation and pregnancy: the effects of diagnsotic 
imaging and radiation therapy In Surbone A., Peccatori F, Pavlidis N Cancer and 
Pregnancy Recent Results in Cancer Research  vol. 178; Springer 2008: 3-20 
www.intechopen.com
 
Melanoma During Pregnancy 
 
97 
Osterlind A, Tucker MA, Stone BJ, et al. (1998)  The Danish case-control study of cutaneous 
malignant melanoma. III. Hormonal and reproductive factors in women. Int J Cancer 
1988; 42(6): 821–824 
Pack GT, Scharnagel IM (1951) Prognosis of malignant melanoma in pregnant women. Cancer 
1951; 4:324–334 
Pages C, Robert C, Thomas L, et al. (2010) Management and outcome of metastatic melanoma 
during pregnancy Br J Dermatol 2010; 162: 274-81 
Patchell RA. (2003) The management of brain metastases. Cancer Treat Rev 2003; 29: 533–540. 
Pavlidis NA. (2002) Coexistence of pregnancy and malignancy. Oncologist 2002; 7: 279–87. 
Pehamberger H, Soyer HP, Steiner A et al. (1998) Adjuvant interferon alfa-2a treatment in 
resected primary stage II cutaneous melanoma. Austrian Malignant Melanoma 
Cooperative Group. J Clin Oncol 1998; 16: 1425–1429. 
Pfahlberg A, Hassan K, Wille L, et al. (1997) Systematic review of case-control studies: oral 
contraceptives show no effect on melanoma risk. Publ Health Rev 1997; 25: 309–315 
Podgorsak MB, Meiler RJ, Kowal H, et al. (1999) Technical management of a pregnant patient 
undergoing radiation therapy to the head and neck. Med Dosim 1999; 24: 121–28. 
Pollitt RA, Geller AC, Brooks DR, et al. (2009)  Efficacy of skin self-examination practices for 
early melanoma detection. Cancer Epidemiol Biomarkers Prev. 2009;18:3018-3023 
Reintgen DS, McCarty KS Jr, Vollmer R, et al. (1985) Malignant melanoma and pregnancy. 
Cancer 1985; 55: 1340–1344 
Richtig E, Soyer HP, Posch M et al. (2005) Prospective, randomized, multicenter, double-blind 
placebo-controlled trial comparing adjuvant interferon alfa and isotretinoin with 
interferon alfa alone in stage IIA and IIB melanoma: European Cooperative Adjuvant 
Melanoma Treatment Study Group. J Clin Oncol 2005; 23:8655–8663. 
Rigel DS, Friedman RJ, Kopf AW et al. (1996) The incidence of malignant melanoma in the 
United States: Issues as we approach the 21st century. J Am Acad Dermatol 1996; 34: 
839–847 
Rigel DS, Russak J, Friedman R (2010) The evolution of melanoma diagnosis: 25 years beyond 
the ABCDs.CA Cancer J Clin. 2010 Sep-Oct;60(5):301-16 
Sadoff L, Winkley J, Tyson S (1998) Is malignant melanoma an endocrinedependent tumor? 
Oncology 1973; 27:244-257 
Sampson JH, Carter JH Jr, Friedman AH, et al. (1998) Demographics, prognosis, and therapy in 
702 patients with brain metastases from malignant melanoma. J Neurosurg 1998; 88: 
11–20. 
Sarnaik AA, Zager JS, Sondak VK. (2007) Multidisciplinary management of special melanoma 
situations: oligometastatic disease and bulky nodal sites. Curr Oncol Rep 2007; 9: 417–427. 
Schadendorf D, Algarra SM, Bastholt L, et al. (2009)  Immunotherapy of distant metastatic 
disease Ann Oncol 2009 Aug;20 Suppl 6: vi41-vi50 
Schmidt AN, Nanney LB, Boyd AS, et al (2006)Oestrogen receptor-beta expression in 
melanocytic lesions. Exp Dermatol 2006;15:971-980 
Scope A, Dusza SW, Halpern AC, et al. (2008) The “ugly duckling” sign: agreement between 
observers. Arch Dermatol. 2008;144:58-64 
Shiu MH, Schottenfeld D, Maclean B, et al. (1976) Adverse effect of pregnancy on melanoma: a 
reappraisal  Cancer. 1976 Jan;37(1):181-7. 
Sim FH, Taylor WF, Pritchard DJ, et al. (1986) Lymphadenectomy in the management of stage 
I malignant melanoma: a prospective randomized study. 1986; Mayo Clin Proc 61: 
697–705 
Slingluff CL Jr, Reintgen DS, Volmer RT, et al. (1990) Malignant melanoma arising during 
pregnancy—a study of 100 patients. Ann Surg 1990; 211: 552–559 
www.intechopen.com
 
Advances in Malignant Melanoma – Clinical and Research Perspectives 
 
98
Smith MA, Fine JA, Barnhill RL, et al. (1998) Hormonal and reproductive influences and risk of 
melanoma in women. Int J Epidemiol 1998; 27(5): 751–757 
Smith RS, Randall P (1969) Melanoma during pregnancy. Obstet Gynecol 1969;34: 825–829 
Squatrito RC, Harlow SP. (1998) Melanoma complicating pregnancy. Obstet Gynecol Clin North 
Am 1998;25:407-16 
Stein M, Fried G, Borovik R, et al. (1990). Malignant melanoma occurring during pregnancy: a 
report of the Northern Israel Oncology Center (1968-1988). J Surg Oncol. 1990 
Oct;45(2):117-20 
Stevens G, McKay MJ. (2006) Dispelling the myths surrounding radiotherapy for treatment of 
cutaneous melanoma. Lancet Oncol 2006; 7: 575–583. 
Stevenson S, Thornton J (2007) Effect of estrogens on skin aging and the potential role of 
SERMs. Clin Interv Aging 2007;2:283-297 
Sutherland CM, Loutfi A, Mather FJ, et al. (1983) Effect of pregnancy upon malignant 
melanoma. Surg Gynecol Obstet 1983; 157:443–446 
Tarhini AA, Agarwala SS. (2004)  Management of brain metastases in patients with melanoma. 
Curr Opin Oncol 2004; 16: 161–166. 
Testori A, Rutkowski P, Marsden J, et al. (2009) Surgery and radiotherapy in the treatment of 
cutaneous melanoma. Ann Oncol. 2009 Aug;20 Suppl 6:vi22-9. 
Trapeznikov NN, Khasanov SR, Iavorskii VV (1987) Melanoma of the skin and pregnancy. 
Voproxy Onkologii 1987;33: 40–46 
Travers RL, Sober AJ, Berwick M, et al. (1995) Increased thickness of pregnancy-associated 
melanoma  Br J Dermatol. 1995 Jun;132(6):876-83. 
Valsecchi ME, Silbermins D, de Rosa N, et al. (2011). Lymphatic Mapping and Sentinel Lymph 
Node Biopsy in Patients With Melanoma: A Meta-Analysis. J Clin Oncol. 2011 Mar 7. 
[Epub ahead of print] 
Van der Giessen PH. (1997) Measurement of the peripheral dose for the tangential breast 
treatment technique with Co-60 gamma radiation and high energy X-rays. Radiother 
Oncol 1997; 42: 257–64. 
Vantroyen B, Vanstraelen D (2002) Management of essential thrombocythemia during 
pregnancy with aspirin, interferon alpha-2a and no treatment. A comparative 
analysis of literature. Acta Haematol 2002; 107: 158–169 
Vongtama R, Safa A, Gallardo D et al. (2003) Efficacy of radiation therapy in the local control 
of desmoplastic malignant melanoma. Head Neck 2003; 25: 423–428. 
Wagner T, Meyer N, Zerdoud S, et al. (2011) FDG PET fails to detect distant metastases at 
initial staging of melanoma patients with metastatic involvement of sentinel lymph 
node. Br J Dermatol. 2011 Feb 17.. [Epub ahead of print] 
Wasif N, Bagaria SP, Ray P, et al. (2011) Does metastasectomy improve survival in patients 
with stage IV melanoma? a cancer registry analysis of outcomes. J Surg Oncol. 2011 
Mar 4. [Epub ahead of print] 
Wheatley K, Ives N, Eggermont AM et al. (2007) Interferon-a as adjuvant therapy for 
melanoma: An individual patient data meta-analysis of randomised trials. 2007 
ASCO Annual Meeting Proceedings Part I. J Clin Oncol 2007: 25 Abstr 8526. 
Wong JH, Sterns EE, Kopald KH, et al. (1989) Prognostic significance of pregnancy in stage I 
melanoma. Arch Surg 1989; 124: 1227–1231  
Yu C, Jozsef G, Apuzzo ML, et al. (2003) Fetal radiation doses for model C gamma knife 
radiosurgery. Neurosurgery 2003; 52: 687–93. 
Zucali R, Marchesini R, De Palo G.(1981)  Abdominal dosimetry for supradiaphragmatic 
irradiation of Hodgkin’s disease in pregnancy: experimental data and clinical 
considerations. Tumori 1981; 67: 203–08. 
www.intechopen.com
Advances in Malignant Melanoma - Clinical and Research
Perspectives
Edited by Dr. April Armstrong
ISBN 978-953-307-575-4
Hard cover, 252 pages
Publisher InTech
Published online 22, September, 2011
Published in print edition September, 2011
InTech Europe
University Campus STeP Ri 
Slavka Krautzeka 83/A 
51000 Rijeka, Croatia 
Phone: +385 (51) 770 447 
Fax: +385 (51) 686 166
www.intechopen.com
InTech China
Unit 405, Office Block, Hotel Equatorial Shanghai 
No.65, Yan An Road (West), Shanghai, 200040, China 
Phone: +86-21-62489820 
Fax: +86-21-62489821
This book titled Advances in Malignant Melanoma - Clinical and Research Perspectives represents an
international effort to highlight advances in our understanding of malignant melanoma from both clinical and
research perspectives. The authors for this book consist of an international group of recognized leaders in
melanoma research and patient care, and they share their unique perspectives regarding melanoma
epidemiology, risk factors, diagnostic and prognostic tools, phenotypes, treatment, and future research
directions. The book is divide into four sections: (1) Epidemiology and Risk Factors of Melanoma, (2) Clinical
Phenotypes of Melanoma, (3) Investigational Treatments for Melanoma and Pigmentary Disorders, and (4)
Advances in Melanoma Translational Research. This book does not attempt to exhaustively cover all aspects
of the aforementioned topics. Rather, it is a compilation of our authorsâ€™ pearls and unique perspectives on
the relevant advances in melanoma during the recent years.
How to reference
In order to correctly reference this scholarly work, feel free to copy and paste the following:
Lazar Popovic, Zorka Grgic and Milica Popovic (2011). Melanoma During Pregnancy, Advances in Malignant
Melanoma - Clinical and Research Perspectives, Dr. April Armstrong (Ed.), ISBN: 978-953-307-575-4, InTech,
Available from: http://www.intechopen.com/books/advances-in-malignant-melanoma-clinical-and-research-
perspectives/melanoma-during-pregnancy
© 2011 The Author(s). Licensee IntechOpen. This chapter is distributed
under the terms of the Creative Commons Attribution-NonCommercial-
ShareAlike-3.0 License, which permits use, distribution and reproduction for
non-commercial purposes, provided the original is properly cited and
derivative works building on this content are distributed under the same
license.
